External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

<ul><li>TMDX is a high-growth med-tech company specializing in organ transplant therapy</li><li>Despite expensive traditional valuation metrics, TMDX offers a compelling investment opportunity</li><li>Company recently became GAAP profitable and free cash flow positive, indicating a bright future ahead</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

TMDX is a high-growth med-tech company specializing in organ transplant therapyDespite expensive traditional valuation metrics, TMDX offers a compelling investment opportunityCompany recently became GAAP profitable and free cash flow positive, indicating a bright future aheadThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Transmedics Group Inc (TMDX) - Thursday, Oct 24, 2024

United States

TransMedics Group, Inc. operates as a biotechnology company. The Company offers transplant therapy for end-stage organ failure patients across multiple disease states. TransMedics Group serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

TransMedics Group (TMDX US)

Transmedics Group Inc (TMDX) - Thursday, Oct 24, 2024

TMDX is a high-growth med-tech company specializing in organ transplant therapy. Despite expensive traditional valuation metrics, TMDX offers a...

Value Investors Club (VIC)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)